Combining a complement inhibitor with rituximab was found to rapidly control severe autoimmune hemolytic anemia (AIHA), including in two patients with cold agglutinin syndrome, a condition related to cold agglutinin disease. In two of the three patients in the series, the complement inhibitor Enjaymo (sutimlimab) was later…
Discussion
Note: This column describes the author’s own experiences with Brukinsa (zanubrutinib). Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. On Saturday, Andy Burcham, the radio play-by-play voice of the Auburn Tigers football team, began his broadcast by saying, “And we’re…
Discussion
My mom returned to her college studies in 1963 when we first moved to Auburn, Alabama. We lived across from the campus of Auburn University and she could easily walk to the buildings where her classes were held. The winter quarter began in January just after the so-called New Year’s…
Discussion
Monday, Aug. 17, was a good day. I don’t usually classify my days as good or bad. They’re just days; something happens or doesn’t happen, and then I go to sleep, and I open my eyes to another day. But something happened on that Monday that had me smiling all…
Discussion
Careful planning, warming measures, and close teamwork between medical specialists may allow for the safe collection and transplant of blood-forming stem cells in people with cold agglutinin disease (CAD) to rebuild a healthy bone marrow after high-dose chemotherapy. That’s according to a study reporting a successful procedure in a…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
